Background: We evaluated the management, outcome and haemorrhagic risk in a cohort of ischaemic stroke patients with mild symptoms treated with intravenous tissue plasminogen activator (tPA) within the first 4.5 h. Methods: We analysed data from a prospective stroke thrombolysis registry. A total of 1,043 patients received tPA between 2010 and 2014 in the 5 stroke units of the RESUVAL stroke network (Rhône Valley, France). Among them, 170 patients had a National Institute of Health Stroke Scale (NIHSS) score ≤4 (minor group: MG) before tPA and 873 patients had a NIHSS score >4. Results: A high rate (77%) of excellent outcome (3-month-modified Rankin Scale score ≤1) was observed in the MG. No symptomatic intracerebral haemorrhage occurred and the rate of any haemorrhagic transformation was 5%. Fifty-four percent of the MG patients had visible arterial occlusion before tPA. Patients of the MG were less likely to be transported by Emergency Medical Services and to be directly admitted to the stroke unit or to imaging. Median delays from onset to admission, from admission to imaging and from onset to tPA were longer in the MG. Conclusion: Our data provided evidence of safety and suggested potential benefit of thrombolysis in patients with NIHSS score ≤4. A majority of these patients exhibited arterial occlusion before thrombolysis. Most often, patients with mild stroke are not given priority in terms of the mode of transport, direct admission to stroke unit and rapid imaging, resulting in an increased delay from onset to thrombolysis. Health system improvements are needed to provide all suspected stroke victims equal access to imaging and treatment on an emergency basis.

Keywords:
Stroke, Thrombolysis, Minor stroke
1.
Cocho D, Belvís R, Martí-Fàbregas J, Molina-Porcel L, Díaz-Manera J, Aleu A, Pagonabarraga J, García-Bargo D, Mauri A, Martí-Vilalta JL: Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005;64:719-720.
2.
Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM: Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020.
3.
Breuer L, Blinzler C, Huttner HB, Kiphuth IC, Schwab S, Köhrmann M: Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of ‘minor stroke'. Cerebrovasc Dis 2011;32:177-185.
4.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35-41.
5.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
6.
Greisenegger S, Seyfang L, Kiechl S, Lang W, Ferrari J; Austrian Stroke Unit Registry Collaborators: Thrombolysis in patients with mild stroke: results from the Austrian stroke unit registry. Stroke 2014;45:765-769.
7.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group: Recombinant tissue plasminogen activator for minor strokes: the national institute of neurological disorders and stroke rt-PA stroke study experience. Ann Emerg Med 2005;46:243-252.
8.
Lindley RI, Wardlaw JM, Whiteley WN, Cohen G, Blackwell L, Murray GD, Sandercock PA; IST-3 Collaborative Group: Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the third international stroke trial. Stroke 2015;46:746-756.
9.
Derex L, Tomsick TA, Brott TG, Lewandowski CA, Frankel MR, Clark W, Starkman S, Spilker J, Udsten GJ, Khoury J, Grotta JC, Broderick JP; EMS Bridging Trial: Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. AJNR Am J Neuroradiol 2001;22:685-690.
10.
Lahoti S, Gokhale S, Caplan L, Michel P, Samson Y, Rosso C, Limaye K, Hinduja A, Singhal A, Ali S, Pettigrew LC, Kryscio R, Dedhia N, Hastak S, Liebeskind DS: Thrombolysis in ischemic stroke without arterial occlusion at presentation. Stroke 2014;45:2722-2727.
11.
Rajajee V, Kidwell C, Starkman S, Ovbiagele B, Alger JR, Villablanca P, Vinuela F, Duckwiler G, Jahan R, Fredieu A, Suzuki S, Saver JL: Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006;67:980-984.
12.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al; EXTEND-IA Investigators: Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009-1018.
13.
Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators: A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:394.
14.
Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS: Factors delaying hospital admission in acute stroke: the Copenhagen stroke study. Neurology 1996;47:383-387.
15.
Derex L, Adeleine P, Nighoghossian N, Honnorat J, Trouillas P: Factors influencing early admission in a French stroke unit. Stroke 2002;33:153-159.
16.
Chang KC, Tseng MC, Tan TY: Prehospital delay after acute stroke in Kaohsiung, Taiwan. Stroke 2004;35:700-704.
17.
Mazighi M, Derex L, Amarenco P: Prehospital stroke care: potential, pitfalls, and future. Curr Opin Neurol 2010;23:31-35.
18.
Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS: Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156-159.
19.
Smith EE, Fonarow GC, Reeves MJ, Cox M, Olson DM, Hernandez AF, Schwamm LH: Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from get with the guidelines-stroke. Stroke 2011;42:3110-3115.
20.
Fischer U, Baumgartner A, Arnold M, Nedeltchev K, Gralla J, De Marchis GM, Kappeler L, Mono ML, Brekenfeld C, Schroth G, Mattle HP: What is a minor stroke? Stroke 2010;41:661-666.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.